Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its…
Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries
SaunaKits.com Opens Its Upstate South Carolina Showroom, Bringing Hands-On Sauna Shopping to the Southeast
Encore Construction Shares Guidance to Help Homeowners Avoid Costly Water Damage Insurance Claim Mistakes